Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has been given a consensus rating of “Buy” by the nine research firms that are covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $21.36.
Several research analysts have recently issued reports on the company. Chardan Capital reissued a “buy” rating and issued a $24.50 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, February 11th. Cantor Fitzgerald set a $24.00 price target on Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, December 11th. Finally, BidaskClub raised Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, February 14th.
In other news, COO Bruce D. Given sold 42,500 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $19.99, for a total value of $849,575.00. Following the completion of the sale, the chief operating officer now owns 687,106 shares in the company, valued at $13,735,248.94. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Bruce D. Given sold 20,000 shares of the company’s stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $11.98, for a total value of $239,600.00. Following the completion of the sale, the chief operating officer now owns 1,118,356 shares of the company’s stock, valued at approximately $13,397,904.88. The disclosure for this sale can be found here. In the last three months, insiders sold 1,045,375 shares of company stock valued at $16,383,268. Company insiders own 4.80% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 1.3% in the fourth quarter. BlackRock Inc. now owns 7,184,621 shares of the biotechnology company’s stock valued at $89,232,000 after buying an additional 92,117 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,951,381 shares of the biotechnology company’s stock valued at $75,748,000 after purchasing an additional 10,273 shares during the last quarter. Vanguard Group Inc lifted its holdings in shares of Arrowhead Pharmaceuticals by 0.3% during the third quarter. Vanguard Group Inc now owns 3,951,381 shares of the biotechnology company’s stock valued at $75,748,000 after purchasing an additional 10,273 shares during the last quarter. Vivo Capital LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 22.6% during the third quarter. Vivo Capital LLC now owns 2,328,475 shares of the biotechnology company’s stock valued at $44,637,000 after purchasing an additional 428,475 shares during the last quarter. Finally, FMR LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter valued at $37,922,000. Institutional investors and hedge funds own 62.24% of the company’s stock.
NASDAQ:ARWR opened at $18.83 on Friday. Arrowhead Pharmaceuticals has a 1 year low of $6.26 and a 1 year high of $22.39. The firm has a market capitalization of $1.77 billion, a PE ratio of -28.97 and a beta of 2.25.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, February 7th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.76 by ($0.63). Arrowhead Pharmaceuticals had a negative return on equity of 24.23% and a negative net margin of 61.78%. The business had revenue of $34.66 million during the quarter, compared to the consensus estimate of $90.88 million. On average, research analysts expect that Arrowhead Pharmaceuticals will post 1.14 EPS for the current year.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Article: The Structure of a Futures Contract
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.